Proteomic analysis of the cerebrospinal fluid of parkinson's disease patients pre-and post-deep brain stimulation

Cellular Physiology and Biochemistry

Volumn 31, Issue 4-5, 2013, Pages 625-637

  Wang, Er Song ^a,b   Yao, Hui Bin ^a   Chen, Ying Hui ^a   Wang, Gan ^b   Gao, Wen Wei ^b   Sun, Yi Rui ^c   Guo, Ji Guang ^d   Hu, Jian Wen ^e   Jiang, Cheng Chuan ^a,c   Hu, Jin ^a,c  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^e Chinese Academy of Sciences   (China)

Author keywords

Cerebrospinal fluid; Deep brain stimulation; Parkinson's disease; Proteomics

Indexed keywords

APOLIPOPROTEIN A1; COMPLEMENT COMPONENT C4; EXTRACELLULAR SUPEROXIDE DISMUTASE; IMMUNOGLOBULIN A; TETRANECTIN; LEVODOPA;

ARTICLE; BRAIN DEPTH STIMULATION; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; WESTERN BLOTTING; ADULT; AGED; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DENSITOMETRY; DRUG DOSE REDUCTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MIDDLE AGED; TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT WITHDRAWAL; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84877662741     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350082     Document Type: Article

References (32)

1. Vitek J: Deep brain stimulation. J Clin Neurophysiol 2004;21:1. (Pubitemid 38507107)
2. Benabid AL, Wallace B, Mitrofanis J, Xia C, Piallat B, Fraix V, Batir A, Krack P, Pollak P, Berger F: Therapeutic electrical stimulation of the central nervous system. C R Biol 2005;328:177-186. (Pubitemid 40247063)
3. Benabid AL, Koudsie A, Benazzouz A, Fraix V, Ashraf A, Le Bas JF, Chabardes S, Pollak P: Subthalamic stimulation for parkinson's disease. Arch Med Res 2000;31:282-289.
4. Lozano AM: Deep brain stimulation for parkinson's disease. Parkinsonism Relat Disord 2001;7:199-203. (Pubitemid 32377168)
5. Volkmann J: Deep brain stimulation for the treatment of parkinson's disease. J Clin Neurophysiol 2004;21:6-17. (Pubitemid 38507109)
6. McIntyre CC, Savasta M, Walter BL, Vitek JL: How does deep brain stimulation work? Present understanding and future questions. J Clin Neurophysiol 2004;21:40-50. (Pubitemid 38507112)
7. Kringelbach ML, Jenkinson N, Owen SL, Aziz TZ: Translational principles of deep brain stimulation. Nat Rev Neurosci 2007;8:623-635. (Pubitemid 47093935)
8. Benabid AL, Chabardes S, Mitrofanis J, Pollak P: Deep brain stimulation of the subthalamic nucleus for the treatment of parkinson's disease. Lancet Neurol 2009;8:67-81.
9. Davidsson P, Sjogren M: The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers 2005;21:81-92. (Pubitemid 40875152)
10. Kim SI, Voshol H, van Oostrum J, Hastings TG, Cascio M, Glucksman MJ: Neuroproteomics: Expression profiling of the brain's proteomes in health and disease. Neurochem Res 2004;29:1317-1331. (Pubitemid 39023504)
11. Ishigami N, Tokuda T, Ikegawa M, Komori M, Kasai T, Kondo T, Matsuyama Y, Nirasawa T, Thiele H, Tashiro K, Nakagawa M: Cerebrospinal fluid proteormc patterns discriminate parkinson's disease and multiple system atrophy. Mov Disord 2012;27:851-857.
12. Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM: Fatal attractions: Abnormal protein aggregation and neuron death in parkinson's disease and lewy body dementia. Cell Death Differ 1998;5:832-837. (Pubitemid 28484393)
13. Paik SR, Lee D, Cho HJ, Lee EN, Chang CS: Oxidized glutathione stimulated the amyloid formation of alpha-synuclein. FEBS Lett 2003;537:63-67. (Pubitemid 36246677)
14. Meredith GE, Halliday GM, Totterdell S: A critical review of the development and importance of proteinaceous aggregates in animal models of parkinson's disease: New insights into lewy body formation. Parkinsonism Relat Disord 2004;10:191-202. (Pubitemid 38534612)
15. McNaught KS, Olanow CW: Protein aggregation in the pathogenesis of familial and sporadic parkinson's disease. Neurobiol Aging 2006;27:530-545. (Pubitemid 43290522)
16. Davidsson P, Paulson L, Hesse C, Blennow K, Nilsson CL: Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. Proteomics 2001;1:444-452. (Pubitemid 33585117)
17. Benabid AL: Deep brain stimulation for parkinson's disease. Curr Opin Neurobiol 2003;13:696-706. (Pubitemid 37518457)
18. Lang AE, Widner H: Deep brain stimulation for parkinson's disease: Patient selection and evaluation. Mov Disord 2002;17:S94-101.
19. Yoav B, Yosef H: On the adaptive control of the false discovery rate in multiple testing with independent statistics. J Behav Educ Statist 2000;25:60-83.
20. Zech H, Echtermeyer C, Wohlbrand L, Blasius B, Rabus R: Biological versus technical variability in 2-d dige experiments with environmental bacteria. Proteomics 2011;11:3380-3389.
21. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, Currie I: A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003;3:36-44. (Pubitemid 36151066)
22. Keeney JT, Swomley AM, Forster S, Hams JL, Sultana R, Butterfield DA: Apolipoprotein a-i: Insights from redox proteomics for its role in neurodegeneration. Proteomics Clin Appl 2013;7:109-122.
23. Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ, Berven FS: Proteomics of human cerebrospinal fluid: Discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J Proteomics 2011;74:371-388.
24. Fattman CL, Schaefer LM, Oury TD: Extracellular superoxide dismutase in biology and medicine. Free Radic Biol Med 2003;35:236-256. (Pubitemid 37288924)
25. Oury TD, Card JP, Klann E: Localization of extracellular superoxide dismutase in adult mouse brain. Brain Res 1999;850:96-103.
26. Obrist P, Spizzo G, Ensinger C, Fong D, Brunhuber T, Schafer G, Varga M, Margreiter R, Amberger A, Gastl G, Christiansen M: Aberrant tetranectin expression in human breast carcinomas as a predictor of survival. J Clin Pathol 2004;57:417-421. (Pubitemid 38446262)
27. Dietzmann K, von Bossanyi P, Krause D, Wittig H, Mawrin C, Kirches E: Expression of the plasminogen activator system and the inhibitors pai-1 and pai-2 in posttraumatic lesions of the cns and brain injuries following dramatic circulatory arrests: An immunohistochemical study. Pathol Res Pract 2000;196:15-21. (Pubitemid 30046522)
28. Stoevring B, Jaliashvili I, Thougaard AV, Ensinger C, Hogdall CK, Rasmussen LS, Sellebjerg F, Christiansen M: Tetranectin in cerebrospinal fluid: Biochemical characterisation and evidence of intrathecal synthesis or selective uptake into csf Clin Chim Acta 2005;359:65-71. (Pubitemid 41116297)
29. Wang ES, Sun Y, Guo JG, Gao X, Hu JW, Zhou L, Hu J, Jiang CC: Tetranectin and apolipoprotein a-i in cerebrospinal fluid as potential biomarkers for parkinson's disease. Acta Neurol Scand 2010;122:350-359.
30. Agorogiannis EI, Agorogiannis GI, Papadimitriou A, Hadjigeorgiou GM: Protein misfolding in neurodegenerative diseases. Neuropathol Appl Neurobiol 2004;30:215-224. (Pubitemid 38789243)
31. Ellisdon AM, Bottomley SP: The role of protein misfolding in the pathogenesis of human diseases. IUBMB Life 2004;56:119-123. (Pubitemid 38661469)
32. Gasser T: Genetics of parkinson's disease. Curr Opin Neurol 2005;18:363-369. (Pubitemid 41104797)